• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利妥昔单抗治疗滤泡性淋巴瘤后出现的活跃外周T细胞反应。

A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma.

作者信息

Frusteri Cristina, Ferrarini Isacco

机构信息

Cancer Research & Cell Biology Laboratory, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy.

出版信息

Ann Hematol. 2024 Dec;103(12):6035-6037. doi: 10.1007/s00277-024-05931-5. Epub 2024 Aug 10.

DOI:10.1007/s00277-024-05931-5
PMID:39122883
Abstract

Bone marrow reactive T-cell infiltrates have been frequently observed in patients affected by follicular lymphoma after rituximab treatment. In some studies, bone-marrow T-cell expansion has been associated with an effective anti-tumor response and favorable prognosis. In this manuscript, we report on a particularly brisk CD4 T-cell reaction occurring after rituximab treatment for follicular lymphoma and involving the peripheral blood in addition to the bone marrow. Peripheral blood T-cell reaction was mainly composed of effector-memory CD4 T cells and may reflect the expansion of an effective anti-tumor immunity.

摘要

在接受利妥昔单抗治疗的滤泡性淋巴瘤患者中，经常观察到骨髓反应性T细胞浸润。在一些研究中，骨髓T细胞扩增与有效的抗肿瘤反应和良好的预后相关。在本手稿中，我们报告了1例在利妥昔单抗治疗滤泡性淋巴瘤后发生的特别活跃的CD4 T细胞反应，该反应除累及骨髓外还累及外周血。外周血T细胞反应主要由效应记忆CD4 T细胞组成，可能反映了有效的抗肿瘤免疫的扩增。

相似文献

1
A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma.利妥昔单抗治疗滤泡性淋巴瘤后出现的活跃外周T细胞反应。
Ann Hematol. 2024 Dec;103(12):6035-6037. doi: 10.1007/s00277-024-05931-5. Epub 2024 Aug 10.
2
T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?利妥昔单抗治疗B细胞滤泡性淋巴瘤后骨髓中的T细胞淋巴样聚集物：治疗效果的标志物？
Hum Pathol. 2008 Feb;39(2):194-200. doi: 10.1016/j.humpath.2007.05.026. Epub 2007 Oct 18.
3
Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?除滤泡性淋巴瘤外，维持性利妥昔单抗在惰性淋巴细胞增殖性疾病中是否有作用？
Leuk Lymphoma. 2017 Jan;58(1):30-36. doi: 10.1080/10428194.2016.1248963. Epub 2016 Nov 4.
4
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.利妥昔单抗时代滤泡性淋巴瘤经活检证实的转化发生率。来自捷克淋巴瘤研究组（CLSG）数据库的回顾性分析。
Ann Hematol. 2018 Apr;97(4):669-678. doi: 10.1007/s00277-017-3218-0. Epub 2018 Jan 9.
5
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.idelalisib、来那度胺和利妥昔单抗在复发难治性淋巴瘤中的安全性和耐受性：肿瘤临床试验联盟A051201和A051202 1期试验
Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.
6
Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.利妥昔单抗治疗后CD20阴性滤泡性淋巴瘤的骨髓浸润：造血细胞和B细胞急性淋巴细胞白血病/淋巴瘤的组织学模仿者
Int J Clin Exp Pathol. 2015 Aug 1;8(8):9737-41. eCollection 2015.
7
Brain Lesion in the Setting of Chronic Rituximab Treatment.慢性利妥昔单抗治疗背景下的脑病变
JAMA Oncol. 2020 Jul 1;6(7):1093-1094. doi: 10.1001/jamaoncol.2020.0160.
8
Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.早期结内和结外滤泡性淋巴瘤受累野照射联合利妥昔单抗治疗后的肿瘤学结果和复发模式分析。
Strahlenther Onkol. 2020 Aug;196(8):705-714. doi: 10.1007/s00066-020-01624-w. Epub 2020 May 6.
9
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).一项由意大利淋巴瘤基金会（FIL）开展的 II 期研究，在老年晚期滤泡淋巴瘤患者中采用利妥昔单抗、苯达莫司汀、米托蒽醌（R-BM）短程诱导，随后进行利妥昔单抗巩固治疗。
Br J Haematol. 2021 Apr;193(2):280-289. doi: 10.1111/bjh.17283. Epub 2021 Jan 21.
10
A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.在利妥昔单抗时代治疗的亚洲患者新发滤泡性淋巴瘤衍生弥漫性大 B 细胞淋巴瘤的临床-基因预后指数。
Sci Rep. 2020 Mar 9;10(1):4373. doi: 10.1038/s41598-020-61378-4.

本文引用的文献

1
Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.长期随访证实，在接受利妥昔单抗维持治疗方案的滤泡性淋巴瘤患者中，大量肿瘤浸润性CD3 T细胞具有良好的预后影响。
Br J Haematol. 2023 Aug;202(3):686-689. doi: 10.1111/bjh.18881. Epub 2023 May 22.
2
Follicular lymphoma: 2020 update on diagnosis and management.滤泡性淋巴瘤：诊断与管理的 2020 年更新。
Am J Hematol. 2020 Mar;95(3):316-327. doi: 10.1002/ajh.25696. Epub 2019 Dec 22.
3
Developmental and Functional Heterogeneity of Monocytes.
单核细胞的发育和功能异质性。
Immunity. 2018 Oct 16;49(4):595-613. doi: 10.1016/j.immuni.2018.10.005.
4
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.Fc 受体相互作用调节细胞毒性和免疫调节治疗性抗体的效应功能。
Cancer Immunol Res. 2015 Jul;3(7):704-13. doi: 10.1158/2326-6066.CIR-15-0120.
5
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice.抗 CD20 治疗通过 IFN-γ/IL-12 轴诱导记忆性 Th1 反应，并防止肿瘤内调节性 T 细胞在小鼠中的扩增。
Leukemia. 2015 Apr;29(4):947-57. doi: 10.1038/leu.2014.275. Epub 2014 Sep 18.
6
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.通过细胞免疫应答的抗 CD20 抗体实现持久的抗肿瘤保护。
Blood. 2010 Aug 12;116(6):926-34. doi: 10.1182/blood-2009-10-248609. Epub 2010 May 3.
7
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.利妥昔单抗免疫疗法可诱导滤泡性淋巴瘤患者产生淋巴瘤独特型特异性T细胞反应：支持利妥昔单抗的“疫苗效应”。
Blood. 2009 Apr 16;113(16):3809-12. doi: 10.1182/blood-2008-10-185280. Epub 2009 Feb 4.
8
T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?利妥昔单抗治疗B细胞滤泡性淋巴瘤后骨髓中的T细胞淋巴样聚集物：治疗效果的标志物？
Hum Pathol. 2008 Feb;39(2):194-200. doi: 10.1016/j.humpath.2007.05.026. Epub 2007 Oct 18.
9
From the bench to the bedside: ways to improve rituximab efficacy.从实验室到临床：提高利妥昔单抗疗效的方法。
Blood. 2004 Nov 1;104(9):2635-42. doi: 10.1182/blood-2004-03-1110. Epub 2004 Jun 29.